{"id":595005,"date":"2022-04-07T17:36:02","date_gmt":"2022-04-07T17:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=595005"},"modified":"2022-04-07T17:36:02","modified_gmt":"2022-04-07T17:36:02","slug":"focal-segmental-glomerulosclerosis-fsgs-pipeline-therapies-clinical-trial-treatment-outlook-companies-retrophin-aurinia-dimerix-complexa-bristolmyers-squibb-and-astellas","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/focal-segmental-glomerulosclerosis-fsgs-pipeline-therapies-clinical-trial-treatment-outlook-companies-retrophin-aurinia-dimerix-complexa-bristolmyers-squibb-and-astellas_595005.html","title":{"rendered":"Focal Segmental Glomerulosclerosis (FSGS) Pipeline, Therapies, Clinical Trial, &#038; Treatment Outlook | Companies &#8211; Retrophin, Aurinia, Dimerix, Complexa, Bristol-Myers Squibb, and Astellas"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1649316104.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Focal Segmental Glomerulosclerosis (FSGS) Pipeline, Therapies, Clinical Trial, &amp; Treatment Outlook | Companies - Retrophin, Aurinia, Dimerix, Complexa, Bristol-Myers Squibb, and Astellas\" src=\"https:\/\/www.abnewswire.com\/uploads\/1649316104.jpeg\" alt=\"Focal Segmental Glomerulosclerosis (FSGS) Pipeline, Therapies, Clinical Trial, &amp; Treatment Outlook | Companies - Retrophin, Aurinia, Dimerix, Complexa, Bristol-Myers Squibb, and Astellas\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Focal Segmental Glomerulosclerosis (FSGS) Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><em>&ldquo;Focal Segmental Glomerulosclerosis Pipeline Insight, 2022&Prime; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis Market.<\/em><\/p>\n<p style=\"text-align: justify;\">The&nbsp;<strong>Focal Segmental Glomerulosclerosis Pipeline<\/strong>&nbsp;report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Focal Segmental Glomerulosclerosis Pipeline Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the&nbsp;<strong>treatment of Focal Segmental Glomerulosclerosis<\/strong>&nbsp;with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Focal Segmental Glomerulosclerosis Treatment.<\/li>\n<li><strong>Focal Segmental Glomerulosclerosis key companies<\/strong>&nbsp;involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li><strong>Focal Segmental Glomerulosclerosis Drugs<\/strong>&nbsp;under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the&nbsp;<strong>Focal Segmental Glomerulosclerosis market<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Focal Segmental Glomerulosclerosis Therapeutics Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><em>The available therapeutics treatment options in the Focal Segmental Glomerulosclerosis (FSGS) landscape aims to reduce complications and protect from further kidney damage. Few companies are performing clinical trials to develop cell therapies and receptor modulators for the treatment of FSGS.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Focal Segmental Glomerulosclerosis (FSGS) Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Retrophin<\/li>\n<li>Aurinia Pharmaceuticals<\/li>\n<li>Dimerix<\/li>\n<li>Complexa<\/li>\n<li>Bristol-Myers Squibb<\/li>\n<li>Astellas Pharma<\/li>\n<li>Pfizer<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others.<\/p>\n<p style=\"text-align: justify;\"><strong>Focal Segmental Glomerulosclerosis (FSGS) Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Sparsentan<\/li>\n<li>Voclosporin<\/li>\n<li>DMX-200<\/li>\n<li>CXA-10<\/li>\n<li>Abatacept<\/li>\n<li>Bleselumab<\/li>\n<li>PF-06730512<\/li>\n<li>And many more.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Focal Segmental Glomerulosclerosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">3. Focal Segmental Glomerulosclerosis Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Focal Segmental Glomerulosclerosis &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Focal Segmental Glomerulosclerosis Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Focal Segmental Glomerulosclerosis Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Focal Segmental Glomerulosclerosis Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Focal Segmental Glomerulosclerosis Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Focal Segmental Glomerulosclerosis Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Focal Segmental Glomerulosclerosis Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Focal Segmental Glomerulosclerosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Focal Segmental Glomerulosclerosis Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Focal Segmental Glomerulosclerosis Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hypothalamic-obesity-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Hypothalamic Obesity Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s&nbsp;<strong>&#8220;Hypothalamic Obesity Market Insights, Epidemiology, and Market Forecast-2032&#8221;<\/strong>&nbsp;report delivers an in-depth understanding of the Hypothalamic Obesity, historical and forecasted epidemiology as well as the Hypothalamic Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=focal-segmental-glomerulosclerosis-fsgs-pipeline-therapies-clinical-trial-treatment-outlook-companies-retrophin-aurinia-dimerix-complexa-bristolmyers-squibb-and-astellas\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=focal-segmental-glomerulosclerosis-fsgs-pipeline-therapies-clinical-trial-treatment-outlook-companies-retrophin-aurinia-dimerix-complexa-bristolmyers-squibb-and-astellas\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Focal Segmental Glomerulosclerosis (FSGS) Pipeline &ldquo;Focal Segmental Glomerulosclerosis Pipeline Insight, 2022&Prime; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis Market. The&nbsp;Focal Segmental Glomerulosclerosis Pipeline&nbsp;report embraces in-depth commercial and clinical &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/focal-segmental-glomerulosclerosis-fsgs-pipeline-therapies-clinical-trial-treatment-outlook-companies-retrophin-aurinia-dimerix-complexa-bristolmyers-squibb-and-astellas_595005.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-595005","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/595005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=595005"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/595005\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=595005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=595005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=595005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}